Studies on cell death and survival regulatory protein c-FLIP as a target for cancer treatment / 中国药理学通报
Chinese Pharmacological Bulletin
; (12): 1496-1502, 2014.
Article
de Zh
| WPRIM
| ID: wpr-459956
Bibliothèque responsable:
WPRO
ABSTRACT
Many tumor cells are resistant to cell apoptosis through the expression of antiapoptotic proteins. c-FLIP is a ma-jor resistance protein of antiapoptosis. In human cells, there are three types of c-FLIP, c-FLIPL , c-FLIPS and c-FLIPR . The c-FLIP binds to FADD to prevent the formation of procaspase-8-DISC and the subsequent activation of caspase cascade. Further-more, c-FLIPL and c-FLIPS have multifunctional roles in various cellular signaling pathways, as well as up-regulating several cyto-protective signaling. Studies show that upregulation of c-FLIP has been found in various tumors, and its downregulation has been shown to restore apoptosis triggered by various chemothera-peutic agents, like the transcriptional regulating agents, trichos-tatin-A, camptothecin, cisplatin, doxorubicin, etc. or other new biotechnologies, such as the specific siRNA. Therefore, c-FLIPS are important targets of cancer therapy. This review summarizes the results on the role of c-FLIP in cancer chemotherapy of tradi-tional antitumor agents and siRNA, and to provide new ideas and rationales of searching for the antiapoptosis effective compounds that can specifically antagonize c-FLIP.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Pharmacological Bulletin
Année:
2014
Type:
Article